The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells
Not yet recruitingOBSERVATIONAL
Enrollment
100
Participants
Timeline
Start Date
May 20, 2025
Primary Completion Date
May 1, 2030
Study Completion Date
May 31, 2030
Conditions
Relapsed B-ALLCAR T-cellsCD19-directed CAR T-cell Therapy
All Listed Sponsors
lead
King Faisal Specialist Hospital & Research Center
OTHER
NCT06993766 - The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells | Biotech Hunter | Biotech Hunter